Targets to Therapies Initiative will de-risk drug development to expand foundational knowledge of underexplored drug targets through a multi-year research program Research ...

Innovation Center Ltd. has led to the discovery of new leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of cancer, leprosy, tuberculosis, colitis, ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

Parkinson’s disease (PD) affects nearly 2% of adults over 65, making it the second most common neurodegenerative disorder. It leads to tremors, stiffness, slow movement, and balance issues due to the ...

"What makes this discovery so significant is the exceptional magnitude of the effect of ITSN1 in increasing Parkinson's risk, especially when compared with variants in other well-established genes ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a significantly elevated risk of Parkinson's disease, a neurodegenerative ...

A newly discovered ITSN1 mutation raises Parkinson’s risk tenfold and may also be linked to autism, opening new doors for research and treatment. Credit: SciTechDaily.com Scientists have identified a ...